Get the Stockscreener App
0.9729
2.71%
-0.0271
Pre-market:
.99
0.0171
+1.76%
Fate Therapeutics Inc stock is traded at $0.9729, with a volume of 1.75M.
It is down -2.71% in the last 24 hours and down -8.22% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.00
Open:
$1.01
24h Volume:
1.75M
Relative Volume:
1.07
Market Cap:
$112.20M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.5896
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-9.92%
1M Performance:
-8.22%
6M Performance:
+2.41%
1Y Performance:
-72.36%
1-Day Range:
$0.95
$1.015
1-Week Range:
$0.95
$1.10
52-Week Range:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9729 | 118.79M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - khodrobank.com
Volume spikes in Fate Therapeutics Inc. stock – what they meanMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Does Fate Therapeutics Inc. show high probability of rebound2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.Market Activity Recap & Risk Controlled Stock Pick Alerts - Newser
Detecting support and resistance levels for Fate Therapeutics Inc.Weekly Stock Recap & Target Return Focused Picks - Newser
Can volume confirm reversal in Fate Therapeutics Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Institutional scanner results for Fate Therapeutics Inc.Trade Volume Summary & Growth Focused Entry Point Reports - Newser
Will Fate Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
Is Fate Therapeutics Inc. trending in predictive chart modelsWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Can machine learning forecast Fate Therapeutics Inc. recoveryPrice Action & Stock Market Timing Techniques - Newser
Fate Therapeutics' Equity Incentive Strategy and Its Implications for Talent Retention and Long-Term Value Creation - AInvest
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics shares rise 3% after-hours following new employee inducement grants. - AInvest
Is Fate Therapeutics Inc. stock entering bullish territoryTrade Exit Summary & Weekly High Potential Alerts - Newser
Leerink Partners lowers Fate Therapeutics stock price target to $7 on iPSC CAR’iT pivot - Investing.com Canada
Does Fate Therapeutics Inc. align with a passive investing strategyInflation Watch & Consistent Income Trade Recommendations - khodrobank.com
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
What are Fate Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Review & Breakout Confirmation Trade Signals - khodrobank.com
Using data models to predict Fate Therapeutics Inc. stock movementJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
What MACD and RSI say about Fate Therapeutics Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Short-Term Trading Alerts - Newser
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Published on: 2025-09-03 09:36:15 - Newser
Has Fate Therapeutics Inc. found a price floorWall Street Watch & Risk Managed Trade Strategies - Newser
Will Fate Therapeutics Inc. stock hit new highs in YEARJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - khodrobank.com
Chart overlay techniques for tracking Fate Therapeutics Inc.2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Building trade automation scripts for Fate Therapeutics Inc.M&A Rumor & Low Risk Entry Point Tips - Newser
Backtesting results for Fate Therapeutics Inc. trading strategiesMarket Trend Review & Smart Allocation Stock Reports - Newser
Market reaction to Fate Therapeutics Inc.’s recent newsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Is Abeona Therapeutics Inc. attractive at current valuation2025 Macro Impact & Consistent Return Investment Signals - khodrobank.com
What is Fate Therapeutics Inc. s 5 year growth outlookTrade Volume Report & Weekly Breakout Stock Alerts - khodrobank.com
Is Fate Therapeutics Inc. forming a bottoming baseJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Fate Therapeutics Inc. Crosses 200 Day MA — Signal or Noise getLinesFromResByArray error: size == 0 - 강소기업뉴스
Will Fate Therapeutics Inc. stock go up soon2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Comparing Fate Therapeutics Inc. in custom built stock radarsRisk Management & Weekly Top Performers Watchlists - Newser
What is Fate Therapeutics Inc.’s valuation compared to sectorMarket Activity Report & Fast Entry Momentum Alerts - khodrobank.com
Published on: 2025-09-01 01:36:52 - Newser
Fate Therapeutics Inc. stock trend forecastEarnings Summary Report & Community Driven Trade Alerts - Newser
Understanding Fate Therapeutics Inc.’s price movementMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
How to interpret RSI for Fate Therapeutics Inc. stockLong Setup & Advanced Technical Analysis Signals - Newser
Tick level data insight on Fate Therapeutics Inc. volatilityWeekly Trade Report & Low Risk Investment Opportunities - Newser
Fate Therapeutics Inc. stock momentum explainedPortfolio Gains Report & Consistent Income Trade Ideas - Newser
RSI Crosses Above 30 for Fate Therapeutics Inc. — Reversal in Sight2025 Key Lessons & Fast Gain Swing Alerts - beatles.ru
Can technical indicators confirm Fate Therapeutics Inc.’s reversalJuly 2025 PostEarnings & Daily Price Action Insights - Newser
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fate Therapeutics Inc Stock (FATE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):